Archives: Speakers

Mark Turner

Mark is a managing director in the London office where he leads the Regulatory Consulting team within Kroll’s Financial Services Compliance and Regulation practice. He specializes in advising the financial services industry on governance, risk management, systems and controls, and regulatory compliance matters.

Prior to Kroll, Mark’s experience includes audit, banking, owning/managing a retail business, regulation and management consultancy. He was a senior risk consultant within the Risk Specialist Division at the Prudential Regulation Authority (PRA), and prior to that the Financial Services Authority (FSA). In recent years, Mark has become one of the industry’s leading experts on individual accountability, and has advised some of the world’s largest financial institutions on the UK’s Senior Managers and Certification Regime (SM&CR). Mark regularly advises Boards and Board Directors on Governance, Risk and Compliance matters, in both contentious and non-contentious situations. He has acted as Skilled Person under s166 (FSMA) on over 30 engagements spanning Governance, Risk, Controls, Client Assets (CASS), Financial Crime and Conduct of Business.

Mark is a Chartered Accountant with over 20 years’ experience within financial services. He holds a BSc in Mathematics from Imperial College, London.

Jo Cook

Previously holding board level leadership roles at FTSE companies including SSE PLC including leading Women in Industry –
Jo is driving innovation at SS&C Blue Prism, As VP of Financial Services, Telco, Utilities, Manufacturing, and Retail teams, leading the business fostering digital business transformation with a strong focus on measured customer outcomes  SS&C collaborative efforts have catalyzed industry success, exemplifying commitment to not just meeting but exceeding expectations.

Catherine Tyner

Catherine Tyner brings 27 years of clinical research experience with a focus on Oversight Group Management for Clinical Endpoint Committees, Data Monitoring Committees, and other operations. Throughout her career, Ms. Tyner has led and developed oversight departments at Quintiles (now IQVIA), Novella Clinical, and Covance (now Fortrea), providing strategic management for over 500 clinical trials, including complex megatrials across diverse therapeutic areas. A recognized thought leader in endpoint adjudication best practices, Ms. Tyner has authored the industry’s seminal guidance on adjudication operations and best practice. In her new role at AG Mednet, Ms. Tyner will work to expand and tailor the value jointly created with new and existing CROs Trial Sponsors, Core Labs, and Academic Research Organizations, working closely to optimize the future of clinical process efficiency.

Anas Qawasmeh

Anas Qawasmeh heads the FinTech & Innovation Business Development team at DIFC Authority, which manages a portfolio of over 1,250 technology companies that leverage DIFC as a strategic hub for their growth, and expansion across the UAE and the region.

With a strong track record in financial technology and innovation, Anas brings a wealth of experience from global industry leading companies. Before joining DIFC, he spearheaded Business Development for FinTech and Ventures at Visa Inc. across the Levant within the Central Europe, Middle East and Africa region.

Prior to Visa, Anas was part of the Strategy Team at ByteDance, the parent company of TikTok. He played a critical role in shaping and leading the finance monetisation strategy during TikTok’s rapid expansion across the Middle East, Turkey, South Africa and Pakistan, contributing to the platform’s regional success and growth.

James Wooster

James is CRO of interop.io, a provider of desktop integration platforms. He has an extensive background in software integration solutions and spent his formative years in a variety of development and architecture roles. Since then, he has run field operations & sales organisations for software integration businesses including SAP’s UK, Software AG Australia and TIBCO UK. 

Nathan Chadwick

With more than a decade of dedicated experience in clinical research, Nathan Chadwick is well-versed in several therapeutic areas, with a specialized focus in neurology and rare disease. At Worldwide, Nathan is at the forefront of therapeutic strategy for rare disease, leading ongoing efforts with rare disease patient advocacy organizations while working to expand rare disease opportunities, studies, and initiatives.